212 related articles for article (PubMed ID: 36010688)
1. Pathogenetic Mechanisms Underlying Spinocerebellar Ataxia Type 3 Are Altered in Primary Oligodendrocyte Culture.
Schuster KH; Putka AF; McLoughlin HS
Cells; 2022 Aug; 11(16):. PubMed ID: 36010688
[TBL] [Abstract][Full Text] [Related]
2. Impaired Oligodendrocyte Maturation Is an Early Feature in SCA3 Disease Pathogenesis.
Schuster KH; Zalon AJ; Zhang H; DiFranco DM; Stec NR; Haque Z; Blumenstein KG; Pierce AM; Guan Y; Paulson HL; McLoughlin HS
J Neurosci; 2022 Feb; 42(8):1604-1617. PubMed ID: 35042771
[TBL] [Abstract][Full Text] [Related]
3. ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice.
Schuster KH; Zalon AJ; DiFranco DM; Putka AF; Stec NR; Jarrah SI; Naeem A; Haque Z; Zhang H; Guan Y; McLoughlin HS
Mol Ther; 2024 May; 32(5):1359-1372. PubMed ID: 38429929
[TBL] [Abstract][Full Text] [Related]
4. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
[TBL] [Abstract][Full Text] [Related]
5. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
[TBL] [Abstract][Full Text] [Related]
6. Disease-associated oligodendrocyte signatures are spatiotemporally dysregulated in spinocerebellar ataxia type 3.
Schuster KH; DiFranco DM; Putka AF; Mato JP; Jarrah SI; Stec NR; Sundararajan VO; McLoughlin HS
Front Neurosci; 2023; 17():1118429. PubMed ID: 36875652
[TBL] [Abstract][Full Text] [Related]
7. A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in Oligodendrocytes.
Haas E; Incebacak RD; Hentrich T; Huridou C; Schmidt T; Casadei N; Maringer Y; Bahl C; Zimmermann F; Mills JD; Aronica E; Riess O; Schulze-Hentrich JM; Hübener-Schmid J
Mol Neurobiol; 2022 Jan; 59(1):495-522. PubMed ID: 34716557
[TBL] [Abstract][Full Text] [Related]
8. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of NF-κB in astrocytes is sufficient to delay neurodegeneration induced by proteotoxicity in neurons.
Li YX; Sibon OCM; Dijkers PF
J Neuroinflammation; 2018 Sep; 15(1):261. PubMed ID: 30205834
[TBL] [Abstract][Full Text] [Related]
10. A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3.
Chen ZS; Huang X; Talbot K; Chan HYE
Cell Death Dis; 2021 Feb; 12(2):136. PubMed ID: 33542212
[TBL] [Abstract][Full Text] [Related]
11. Autophagy Promoted the Degradation of Mutant ATXN3 in Neurally Differentiated Spinocerebellar Ataxia-3 Human Induced Pluripotent Stem Cells.
Ou Z; Luo M; Niu X; Chen Y; Xie Y; He W; Song B; Xian Y; Fan D; OuYang S; Sun X
Biomed Res Int; 2016; 2016():6701793. PubMed ID: 27847820
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model.
Toonen LJA; Overzier M; Evers MM; Leon LG; van der Zeeuw SAJ; Mei H; Kielbasa SM; Goeman JJ; Hettne KM; Magnusson OT; Poirel M; Seyer A; 't Hoen PAC; van Roon-Mom WMC
Mol Neurodegener; 2018 Jun; 13(1):31. PubMed ID: 29929540
[TBL] [Abstract][Full Text] [Related]
13. Generation of an induced pluripotent stem cell line from a patient with spinocerebellar ataxia type 3 (SCA3): HIHCNi002-A.
Hayer SN; Schelling Y; Huebener-Schmid J; Weber JJ; Hauser S; Schöls L
Stem Cell Res; 2018 Jul; 30():171-174. PubMed ID: 29936336
[TBL] [Abstract][Full Text] [Related]
14. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
Li X; Liu H; Fischhaber PL; Tang TS
Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
[TBL] [Abstract][Full Text] [Related]
15. Ataxin-3, The Spinocerebellar Ataxia Type 3 Neurodegenerative Disorder Protein, Affects Mast Cell Functions.
Sowa AS; Haas E; Hübener-Schmid J; Lorentz A
Front Immunol; 2022; 13():870966. PubMed ID: 35558088
[TBL] [Abstract][Full Text] [Related]
16. Differential recruitment of UBQLN2 to nuclear inclusions in the polyglutamine diseases HD and SCA3.
Zeng L; Wang B; Merillat SA; Minakawa EN; Perkins MD; Ramani B; Tallaksen-Greene SJ; Costa MDC; Albin RL; Paulson HL
Neurobiol Dis; 2015 Oct; 82():281-288. PubMed ID: 26141599
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological enhancement of retinoid-related orphan receptor α function mitigates spinocerebellar ataxia type 3 pathology.
Watanave M; Hoshino C; Konno A; Fukuzaki Y; Matsuzaki Y; Ishitani T; Hirai H
Neurobiol Dis; 2019 Jan; 121():263-273. PubMed ID: 30343032
[TBL] [Abstract][Full Text] [Related]
18. Altered retinal structure and function in Spinocerebellar ataxia type 3.
Toulis V; Casaroli-Marano R; Camós-Carreras A; Figueras-Roca M; Sánchez-Dalmau B; Muñoz E; Ashraf NS; Ferreira AF; Khan N; Marfany G; Costa MDC
Neurobiol Dis; 2022 Aug; 170():105774. PubMed ID: 35605759
[TBL] [Abstract][Full Text] [Related]
19. From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to Translation.
Da Silva JD; Teixeira-Castro A; Maciel P
Neurotherapeutics; 2019 Oct; 16(4):1009-1031. PubMed ID: 31691128
[TBL] [Abstract][Full Text] [Related]
20. Deficiency in classical nonhomologous end-joining-mediated repair of transcribed genes is linked to SCA3 pathogenesis.
Chakraborty A; Tapryal N; Venkova T; Mitra J; Vasquez V; Sarker AH; Duarte-Silva S; Huai W; Ashizawa T; Ghosh G; Maciel P; Sarkar PS; Hegde ML; Chen X; Hazra TK
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8154-8165. PubMed ID: 32205441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]